Feb 9 (Reuters) - The U.S. Food and Drug Administration

said a television advertisement for Novo Nordisk's

weight-loss pill is "false ‌or misleading", according to a letter

dated February 5.

The ​health regulator said the television spot misleadingly

suggests ‍that Wegovy in its pill ⁠form offers ⁠an advancement or

improvement over other weight-loss drugs that ‌belong to the

class known ​as GLP-1s.

The FDA also said the claims "live lighter" and "a way

forward" misleadingly ⁠imply additional weight ‍loss ​compared to

other currently approved GLP-1 treatments, when this has not

been demonstrated.

The Danish company ‍did not immediately respond to Reuters

request for comment.

"Additionally, they misleadingly imply benefits beyond

physical weight loss, such as emotional relief, reduced

psychological burden, hope, or direction for ​patients' ‍lives,

positioning the drug as a solution to broader life challenges

rather than ​a treatment for a specific condition, when this has

also not been demonstrated," the agency said in the letter.

The agency said the Novo ad was in violation of the Federal

Food, ​Drug, and Cosmetic Act, and asked the drugmaker to take

immediate action to address any violations.